Benzinga | Aug 3, 2021 07:28AM EDT

ADC Therapeutics Q2 Adj. EPS $(0.70) Beats $(0.82) Estimate, Sales $3.76M Beat $2.37M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.82) by 14.63 percent. This is a 37.25 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $3.76 million which beat the analyst consensus estimate of $2.37 million by 58.65 percent.